Argenx Surges to 401st in Trading Volume with $254 Million Day as Citi Analysts See Buy Opportunity

On May 21, 2025, Argenx (ARGX) saw a significant surge in trading volume, reaching $254 million, marking a 38.94% increase from the previous day. This surge placed Argenx at the 401st position in terms of trading volume for the day. The stock price also rose by 1.15%, extending its winning streak to five consecutive days, with a total gain of 9.90% over the past five days.

Citi analyst Samantha Semenkow maintains a positive outlook on Argenx, asserting that the company's growth narrative remains robust despite concerns about a slowing launch of Vyvgart. She views the recent market pullback as an attractive buying opportunity, driven by expectations of sustained Vyvgart growth and favorable risk/reward dynamics ahead of pipeline readouts. The recent approval of a prefilled syringe with a "best-case label" and the ongoing expansion of the chronic inflammatory demyelinating polyneuropathy launch are expected to bolster Vyvgart's momentum in the near term. Citi has reiterated its Buy rating on Argenx with a price target of $803, emphasizing the current pullback as an opportune moment for investors.

Argenx's stock is also noted for its relatively low price-to-earnings (P/E) ratio, which may indicate that the stock is undervalued. This lower P/E ratio could make Argenx an appealing investment opportunity for those looking to capitalize on potential market undervaluation.